Saturday, February 9, 2008

LEXIVA is contraindicated with plant disease derivatives.

Skin rashes (all grades, without stare to causality) occurred in approximately 19 percent of patients treated with LEXIVA in the pivotal efficacy studies. This led to the discontinuation of LEXIVA in less than 1 percent of patients.


During the initial state of matter of handling, patients responding to antiretroviral therapy may develop an inflammatory issue to indolent or remainder opportunistic infections.


LEXIVA is contraindicated with plant disease derivatives, cisapride, pimozide, midazolam and triazolam. If LEXIVA is coadministered with ritonavir, flecainide and propafenone are also contraindicated. Care should be used when coadministering medications that are substrates, inhibitors or inducers of CYP3A4, or potentially toxic medications that are metabolized by CYP3A4. Serious and/or life-threatening drug interactions could occur between LEXIVA and amiodarone, lidocaine (systemic), tricyclic antidepressants and quinidine. Tightness monitoring of these agents is recommended if these agents are used concomitantly with LEXIVA. LEXIVA should not be coadministered with rifampin, St. John'swort, lovastatin, simvastatin or delavirdine.

No comments: